Gallium Ga 68-labeled PSMA-11 PET/CT or PET/MRI in Diagnosing Patients with Biomedical Recurrent Prostate Cancer

Inclusion Criteria

• Histopathologically proven prostate adenocarcinoma
• Rising PSA (at least two consecutive rising PSAs) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy) * Post radical prostatectomy (RP) – American Urological Association (AUA) recommendation for biochemical recurrence after radical prostatectomy ** PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after RP * Post-radiation therapy–American Society for Radiation Oncology (ASTRO)-Phoenix consensus definition of biochemical recurrence after radiation therapy ** Nadir + greater than or equal to 2 ng/mL rise in PSA
• Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
• Ability to understand a written informed consent document, and the willingness to sign it

Exclusion Criteria

• Unable to lie flat, still or tolerate a PET scan
• Concomitant investigational therapy
• Patient undergoing active treatment for non-prostate malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer
• Contraindication to furosemide administration including prior allergy or adverse reaction to furosemide or sulfa drugs; (Note: This exclusion criteria can be removed if furosemide is omitted as part of the PET imaging protocol if a second-generation scatter correction is available for the used PET device)